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Parkinson’s disease (PD) as an increasing clinical syndrome is a multifunctional
impairment with systemic involvement. At present, therapeutic approaches such
as L‐3,4‐dihydroxy‐phenylalanine replacement therapy, dopaminergic agonist
administration, and neurosurgical treatment intend to relieve PD symptoms
which are palliative and incompetent in counteracting PD progression. These
mentioned therapies have not been able to replace the lost cells and they could
not effectively slow down the relentless neurodegenerative process. Till now,
there is a lack of eligible treatment for PD, and stem cells therapy recently has
been considered for PD treatment. In this review, we demonstrate how human
stem cell technology especially human endometrium‐derived stem cells have made
advancement as a therapeutic source for PD compared with other treatments.
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1 | INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative disease,
and it is the second most common neurodegenerative disorder
characterized by motor and nonmotor symptoms. It is expected to
impose an increasing economic and social burden on human
populations. The greatest risk factor of PD is age and the incidence
rate of PD generally increases with it (Dowding, Shenton, & Salek,
2006; Stefanis, 2012; Zhang et al., 2015). The motor symptoms of PD
are well known, including age‐dependent uncontrollable resting
tremor, bradykinesia, rigidity, posture instability (Dowding et al.,
2006; Kalia et al., 2015), and other debilitating symptoms which are
caused by the degeneration of dopaminergic (DA) neurons in the
substantia nigra pars compacta (SNpc), a region in the ventral
midbrain, and neurons from other regions of the peripheral and
central nervous systems (CNS). During the unbeknown preclinical
course, degeneration of non‐DA neurons in the brainstem, olfactory
bulb, and cortex has already occurred insidiously (Braak et al., 2003;
Deuschl et al., 2006; Sundberg & Isacson, 2014). In the nonmotor
symptoms, cognitive changes, dementia, behavioral or neuropsychia-
tric changes, pain and fatigue, autonomic dysfunction, psychosis and
hallucinations, sleep disorder, depression, mood disturbances, and
anxiety occur (Kostić et al., 2012). The pathogenetic mechanisms
underlying the selective DA cell loss in PD are mitochondrial
dysfunction, oxidative stress, and protein mishandling (Greenamyre
& Hastings, 2004). The emergence of new drugs and technologies has
been expanded in the last few decades as a choice of treatment in
curing PD (Buttery & Barker, 2014). Currently, available therapeutic
approaches are mainly aiming to relief PD motor symptoms including
L‐3,4‐dihydroxy‐phenylalanine (L‐DOPA) replacement therapy, ad-
ministration of DA agonist, and deep brain stimulation (DBS; Foltynie
& Hariz, 2010), in subthalamic nucleus and globus pallidus via
surgically implanted electrodes (Politis & Lindvall, 2012). All of these
therapeutic approaches are palliative and they are incapable for
contrary to progression of PD (Buttery & Barker, 2014). Many
common neurological disorders, including PD, are caused by a loss of
neurons and glial cells. In recent years, neurons and glia have been
generated successfully from stem cells in vitro to develop stem cell‐
based transplantation therapies for human patients (Han, Chaineau,
Chen, Beitel, & Durcan, 2018; Lindvall & Kokaia, 2006). The aim of
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the review is to make a comparison of cell therapy and other
treatment ways as a therapeutic application in PD and to suggest the
best therapeutic strategy towards the treatment of PD.
2 | ORAL DA THERAPIES FOR PD
Current pharmacotherapy treatment is the oral administration of L‐
DOPA and other DA and non‐DA drugs. General treatment for PD is
medication with L‐DOPA. L‐DOPA is used because unlike dopamine it
can pass the blood–brain barrier. It is converted to dopamine by DA
neurons. But, the progressive loss of DA neurons results in the
brain’s inability to convert the drug to dopamine regardless of the
dosage. After long‐term L‐DOPA intake patients show side effects,
such as on–off phenomena, wearing‐off, motor fluctuations, and
dyskinesia (Deuschl et al., 2006). Patients can alternate between “on”
states, which can be complicated by disabling dyskinesias, and “off”
states, in which patients are akinetic (Han et al., 2018; Kreitzer &
Malenka, 2008). Another problem of long‐term oral L‐DOPA therapy
is cognitive impairment. DA drugs were classified as dopamine
receptor agonists contain catechol‐O‐methyltransferase (COMT) and
monoamine oxidase (MAO) inhibitors (Jankovic & Stacy, 2007).
Treatment with COMT and MAO inhibitors can reduce the motor
fluctuations symptom. Using MAO inhibitors can prolong the
duration of L‐DOPA action time (Sari & Khalil, 2015). But, in the
progressive loss of DA neurons in advancing stage of disease and the
appearance of L‐DOPA‐induced dyskinesia (LID), these therapies
show their limitations (Behari & Singhal, 2011). The N‐methyl‐D‐
aspartate (NMDA) receptor antagonist as a non‐DA drugs like
amantadine that have mild symptomatic benefits and can decrease
LID in some patients (Rascol, Perez‐Lloret, & Ferreira, 2015). Non‐DA
drugs like antagonist of metabotropic glutamate receptors is still
under animal experiment and clinical trials (Pahwa et al., 2015).
3 | NEUROSURGICAL TREATMENT OF PD
Neurosurgical treatment (i.e., DBS) was used in advanced stage of
disease (Miller et al., 2016; Verhagen Metman, Pal, & Slavin, 2016).
In PD, functional neurosurgery can be achieved by globus pallidus
internus (GPi) DBS and pallidotomy and subthalamic nucleus DBS,
and subthalamotomy (Poortvliet, Silburn, Coyne, & Chenery,
2015; Hamani et al., 2008). DBS creates stimulation in subthalamic
nucleus (STN‐DBS; Deuschl et al., 2006). The subthalamic nucleus
deep brain stimulation can reduce the DA drug dose (Munhoz,
Cerasa, & Okun, 2014; Poortvliet et al., 2015) and improves the
cardinal motor features of tremor, rigidity and slowness, while the
GPi surgery has a direct effect on dyskinesia (Deuschl et al., 2006).
STN‐DBS is not suggested as an effective therapy, because the
neurosurgical treatment is restricted to certain patients, by assessing
the axial and gait symptoms progress despite surgery (Yarnall,
Rochester, & Burn, 2011). In some cases, the brainstem pedunculo-
pontine nucleus (PPN) has also been targeted. The result of PPN‐DBS
remains unidentified (Ferraye et al., 2010). In DBS, the disease
progression is unaltered and the nonmotor symptoms and cognitive
symptoms were untouched in certain patients (Temel et al., 2006).
DBS has slight or no impact as a cure in neurodegeneration disease in
human (Aybek et al., 2007). Hence, from the above data, it is said that
DBS remains for specific symptoms. Thus, it is not an appropriate
treatment for PD and the nigrostriatal‐mediated motor impairment
still lacked an adequate solution.
4 | CURRENT EXPERIMENTAL STUDIES OF
GENE THERAPY IN PD
In PD, degeneration of midbrain DA neurons leads to dopamine loss
within the striatum and causes severe motor disorder that includes
rigidity, tremor, and akinesia (the inability to initiate movement; Shen
et al., 2000). In experiments where high concentrations of dopamine
were applied the patients showed better outcomes. In the CNS, gene
therapy allows the continuous production of dopamine in a target‐
specific manner (Kordower et al., 2000).The preference of gene
therapy was that we can deliver a specific gene as an agent to the
certain region of brain to alter function and improve disease (Stayte
& Vissel, 2014), while avoiding the off‐target effects (Allen & Feigin,
2014). Gene therapy restores sufficient dopamine concentration in
the striatum and restores normal functioning of the basal ganglia
networks, as demonstrated by our data showing normalization of
neuronal activity in the GPi and of STN metabolism (Lang & Lozano,
1998). Although gene therapy is mostly experimental at current
status, it has large capacity to become a new class of therapeutic
strategy for PD in near future. Identifying the appropriate delivery
method is the first step for treating PD by gene therapy (Oertel &
Schulz, 2016). Although the measures we adopted to remedy such a
problem needs a lot of precautions, the measures themselves are
limited by a lot of issues, for example, appropriate delivery vector
selection (Latchman & Coffin, 2001; Muramatsu, 2002; Lewis et al.,
2014). According to recent research, gene therapy shows high
potential as an important treatment modality for future PD therapy.
5 | THERAPEUTIC EFFECT OF CELL
THERAPY IN PD
PD is a clinical syndrome with multifunctional impairment and
systemic involvement disease (Fahn, 2003). Therapeutic approaches
such as L‐DOPA therapy, DA drug, and neurosurgical treatment
intend to relieve PD motor symptoms (Foltynie & Hariz, 2010), which
are palliative and incompetent in counteracting disease progression,
and these therapies have not been able to replace the lost cells or
effectively decelerate the neurodegeneration process. As yet, there is
no certain treatment for PD which shows the shift to stem cell
therapy research recently has been a therapeutic method in curing
PD (Lindvall & Kokaia, 2006). In recent years, expand of using stem
cell promise the revolution of medical therapy for neurological
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disorders such as PD, Alzheimer disease, and multiple sclerosis (MS;
Freed et al., 2001; Han et al., 2018; Olanow et al., 2003). Stem cells
are defined as cells with both multipotency and self‐renewal features.
Multipotency is the ability to differentiate into several different
types of cells; self‐renewal is the ability to divide and proliferate into
the same cell type (Mirzaei et al., 2016; Evans & Kaufman, 1981;
Takahashi & Yamanaka, 2006). By the progress of stem cell therapy,
many cells have been used for DA neurons derivation and
differentiation, drug screening, and cell therapy for PD. Currently,
there are embryonic stem cells (ESCs), induced pluripotent stem cells
(iPSCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs)
have been used as a proper therapeutic way for PD treatment (Duke
& Taylor, 2013; Kirkeby et al., 2012; Sundberg et al., 2013; Zhang
et al., 2016). Treating neurodegenerative diseases with cell therapy
has been within reach since the first pioneering clinical trials in which
DA progenitors from the fetal brain were transplanted to individuals
with PD (Parmar, 2018). Also, open‐label phase I study in patients
with MS shows that repeated administration of intrathecally injected
bone marrow‐derived MSC‐neural progenitors is safe and well
tolerated (Harris et al., 2018).
Stem cell technologies introduce new way for the treatment
of diverse brain diseases. Many experimental models of PD have
been developed to study the efficiency and feasibility of cell‐
replacement therapies in animals. Many of those models utilize
1‐methyl‐4 phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) or 6‐hy-
droxydopamine (6‐OHDA) to induce selective neurotoxicity of
the nigral DA neurons and parkinsonism in the recipient animals.
Subsequent transplantation of ESCs, iPSCs, and other stem cells
has resulted in various degrees of success in replacing DA
neurons. However, ethical considerations, difficulties in finding a
continuous supply of some stem cells like ESCs and the risk of
tumorigenicity after ESCs or iPSCs transplant that have been
reprogrammed to a pluripotent state, which prevent their
potential clinical application. MSCs represent a promising tool
for cell‐replacement therapy in neurological diseases. Previous
research about MSCs application has shown their ability to
promote endogenous neural growth, induce synaptic formation,
reduce levels of free radicals in the microenvironment, decrease
apoptosis, and regulate inflammation. In PD the selective DA cell
degeneration has been used for novel cell‐replacement strategies
to restore dopamine supply to the striatum area. The recent
upcoming research for PD treatment using human endometrium‐
derived stem cells (HEDSCs) has unveiled in bringing stem cell
technology in the expected future in the form of disease modeling
and stem cell therapy (Figure 1; Ai et al., 2012; Crigler, Robey,
Asawachaicharn, Gaupp, & Phinney, 2006; Danielyan et al., 2011;
Hardy, Maltman, & Przyborski, 2008; Dominici et al., 2006; Wolff
et al., 2011).
6 | ESCs
ESCs have the ability to self‐renew and can give rise to primary germ
layer under certain condition. The essential characteristics were
needed for employing human ESCs as a therapeutic goal (Thomson
et al., 1998). Transplanted human ESCs in the striatum area of rat PD
model develop into functional DA neurons with a substantia nigra
phenotype. Grafts of dopamine neurons survive and improve
behavioral function in rat model of PD. However, the DA‐enriched
grafts contained tumourigenic cells and mitotic undifferentiated
neuroepithelial cells. This study accomplished by Kriks et al. (2011)
was the most important breakthrough in this field (Roy et al., 2006).
Previous study on 6‐OHDA lesioned rat PD model showed the
effects of transplantation of mouse ESCs produced functional DA
neurons (Bjorklund et al., 2002). Quantitative measurements and
positron emission tomography scans showed a significant improve-
ment of symptoms in the rats (Kim et al., 2002). But this experiment
showed the side effects of tumor formation and graft failure. Beside,
F IGURE 1 The human uterus
endometrium and derived stem cells. The
superficial layer (functionalis) is shed
during menstruation, whereas the
permanent bottom layer (basalis) gives rise
to the regeneration of endometrium after
each menstruation. These layers include
dividing, post‐mitotic, progenitor, and stem
cells [Color figure can be viewed at
wileyonlinelibrary.com]
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a research published in nature demonstrated that the differentiation
of ESCs into DA neurons in vitro before transplantation proved to be
functional and it concluded that the tumor formation is an
inadmissible one. Hence, future experiments needed to understand
the safety and efficacy of ESCs transplantation (Kim et al., 2002).
Normal embryonic development and differentiation as well require
several morphogenesis factors such as epidermal growth factor
(EGF), fibroblast growth factor (FGF), sonic hedgehog, and glial cell‐
derived neurotrophic factor as neurogenic stimulators showed in
vitro ESCs. Differentiation follows special approaches (Buytaert‐
Hoefen, Alvarez, & Freed, 2004; Ross, McCaffery, Drager, & De Luca,
2000). Differentiation protocol and culture methods can improve in
creating a scalable population of DA neurons (A9‐type) specific to the
ventrolateral and caudal regions of the substantia nigra. Though
malapropos innervations and graft‐induced dyskinesias in animal
models showed increased fiber outgrowth which has seen improved
outcomes. Genetic modification of these implanted neurons could
limit the excessive outgrowth (Ambasudhan et al., 2014). Finally,
using ESCs for therapeutic aims and difficulties are clearly demon-
strated and also limited and reveal complicated ethical questions.
7 | iPSCs
Almost 10 years ago, the first report describing iPSCs methodology was
published. IPSCs have advantages over other stem cell types as they can
be reprogrammed from patients own somatic cells, thus eliminating
worries about the ethics of using ES cells and the probability of immune
rejection of ES‐cell‐derived tissues (Kiskinis & Eggan, 2010; Mohseni,
Shoae‐Hassani, & Verdi, 2015). Researchers can generate iPSCs from
skin, blood, urine‐derived cells, or fetal tissue (Han et al., 2018; Parmar,
2018). IPS cell technology represents a novel venue toward disease
models for neurodegenerative disorders and provides an unlimited
source of native phenotypes of cells involved in neuronal death
(Takahashi et al., 2007; Zhang, Ge, Hao, & Dong, 2018). Fundamental
issue underlies the modeling PD using iPSC is an aging factor, iPSC
should be a critical part in reconstructing late‐onset characteristics
(Moretti et al., 2010; Zhang et al., 2011). Treatment of PD patient by
employing iPSC can confirm the pathophysiological effect of the late‐
onset neurodegenerative disorder (Marote et al., 2018; Miller et al.,
2013). The risk of tumorigenicity and infection of the iPS cell‐derived
donor cells associated with iPS cell‐based therapy. A major concern with
using the iPS cells is tumorigenicity. In some cases, human cells grafting
proliferate and form masses in animal brains that consequently
compressed the nearby brain structure (Doi et al., 2012; Morizane
et al., 2006). High proliferative residual immature cells in the graft can
apparently cause tumor formation. The teratoma risk substantially
dependents on the residual iPSCs in the donor cells. Besides immature
neural cells can proliferate unpredictably, resulting in graft overgrowth
in an experiment with the PDmodel. Hence, great research in producing
donor cells from iPSCs efforts concentrate on the development of new
approaches to regulate the direction of the cell phenotype and the
extent of maturation (Adil & Schaffer, 2018; Doi et al., 2012). On the
other hand, the poor graft survival rate was accentuated by using
mature transplanted neural cells.
8 | NSCs
NSCs can give rise to neurons, astrocytes, and oligodendrocyte, but
are not capable of differentiating into hepatocytes, cardiac muscles,
or other cell types unrelated to the neural system (Gage, Ray, &
Fisher, 1995; Shen et al., 2016; Shoae‐Hassani, Sharif, Tabatabaei, &
Verdi, 2011). Due to the obliteration of brain DA neurons in PD,
NSCs could be a good candidate as a novel source of cell therapy in
this disease (Shen et al., 2016). Their use as graft material in the brain
may be considered as a possible therapeutic mean for PD. Human
neural precursor cells as the immune practical value would be useful
for scientists and likewise clinical neural transplantation trials
(L’episcopo et al., 2018; Shen et al., 2016). Human‐induced neural
stem cells can be obtained from some parts of developing human
nervous system such as the hippocampal dentate gyrus and
subventricular zone and probably the olfactory bulb (Eriksson
et al., 1998; Spalding et al., 2013). Evaluation of NSCs grafted in
PD model, revealed that NSCs can incorporate into the nigrostriatal
pathway and reinstate the projection of substantia nigra to striatum
and relief PD symptoms by stimulation of dopamine synthesis and
release (Harrower, Tyers, Hooks, & Barker, 2006; O’Keeffe et al.,
2008; Redmond et al., 2007). NSCs have a remarkable property to
develop various neural cells such as neurons and glia, and migration
into lesion areas of the brain and especially striatum area, thus it
could be interpreted that NSCs are the proper choice for PD
treatment. One challenge of using adult NSCs in the treatment of PD
is the fact that collection of adult NSCs is a difficult process and the
risk of CNS tissue damage always exist (Fricker et al., 1999; Svendsen
et al., 1997). Injection of NSCs into the striatum of PD patient leads
to rising dopamine concentration in the implanted putamen along
with durable enhancement in unified PD rating scales scores
(Levesque, Neuman, & Rezak, 2009). In general, isolation and enough
expansion of NSCs from the CNS are so tough in vitro and require
culture medium supplemented with mitogenic growth factors, such as
EGF and basic FGF. Dramatically, the application of NSCs to large‐
scale clinical states is lacking. Treating neural disorder with stem cells
pursues to decline neural inflammation and decelerate neural
degeneration through repercussions the special effects of the
transplanted stem cells exerted by neurotrophic factors but not to
renovate the neural circuit (Gage et al., 1995; Ostenfeld & Svendsen,
2004; Thomson et al., 1998).
9 | MSCs
MSCs have shown their ability to promote endogenous neural
growth, induce synaptic formation, multipotency features, and they
are nonhematopoietic stem cells which adhere to the flask surface
(Zarrabi, Mousavi, Abroun, & Sadeghi, 2014). MSCs show less
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immunological reaction than other adult stem cells, due to the lack of
major histocompatibility complex II (MHC‐II) (Morandi, Raffaghello,
& Bianchi, 2008). The facility and feasibility of preparation has turned
MSCs into most used stem cell types for cell‐replacement therapy.
We can use various strategies to improve the cell adhesion and
survival of the transplanted MSCs by inducing the overexpression of
adhesion molecules or antiapoptotic signals such as pretreatment
with growth factors or cytokines, hypoxic preconditioning, and
genetic modifications (Khademi et al., 2017; Verdi, Tan, Shoae‐
Hassani, & Seifalian, 2014; Lee, Choi, Cha, & Hwang, 2015). Bone
marrow‐derived MSCs were originally identified and cultured as
clonogenic fibroblasts (CFU‐F). It became appearance that plastic
adherent bone marrow cultures comprised MSCs as well as
fibroblasts, and to reflect this heterogeneity, they were recently
renamed multipotent mesenchymal stromal cells and the MSC
acronym was retained. MSCs have been detected in the endome-
trium (Gargett, Schwab, Zillwood, Nguyen, & Wu, 2009; Schwab &
Gargett, 2007), adipose tissue (Zuk et al., 2002) and many other
organs over the last decade (Crisan et al., 2008). The eminent
features of HBM‐MSCs are multilineage differentiation into bone,
clonogenicity, plastic adherence, and marrow lineages (osteocytes,
chondrocytes, and adipocytes) in vitro and a surface phenotype
(CD29+, CD44+, CD73+, CD90+, CD105+, CD146+, CD312, CD342,
and CD452) distinguishing them from haematopoietic stem cells
(HSCs) also resident in marrow (Dominici et al., 2006; Verdi et al.,
2014). HEDSCs (Cervelló et al., 2010; Gargett et al., 2009) and the
human CD146 + PDGFR‐b + and SUSD2+ (sushi domain containing‐2
[previously W5C5+]) or endometrial stromal subpopulations
(Schwab & Gargett, 2007; Masuda, Anwar, Bühring, Rao, & Gargett,
2012) have the same in vitro features as bmMSCs. In vitro cultured
fibroblasts from the endometrium (stromal cells), bone marrow, and
many tissues also show these classic bmMSC features, prompting
biologists to question the utility of these stem cells defining features
(Figure 2; Bianco et al., 2013; Hematti, 2012; Phinney & Sensebé,
2013; Shoae‐Hassani et al., 2013; Verdi et al., 2014).
10 | HUMAN UMBILICAL CORD ‐DERIVED
MSCs (HUC‐MSCs)
HUC‐MSCs can be collected with a noninvasive method. For
recipient patients, HUC‐MSCs are an allogeneic cell source, but this
stem cells show low immune reaction, so cannot motivate allocative
lymphocyte proliferation. HUC‐MSCs transplanted that have been
low risk for tumor formation in the transplantation therapies into
animal models (Kim, Jeon, Yang, Oh, & Chang, 2010; Moradian
Tehrani et al., 2017). In cell therapy for PD rat model, (Bernstein &
Shearer, 1988) just reported human bone marrow‐derived MSCs
(HUC‐MSCs) could be differentiated into DA neurons in the striatum
area and observed that the cell‐replacement therapy obtained partial
improvement in lesion region (Bernstein & Shearer, 1988). The
research showed differentiation and neuroprotection of DA neurons
were related to the neurturin genes. Transfection of HUC‐MSCs with
neurturin gene by recombinant adenovirus and increasing of
neurturin concentration and neuron‐specific markers in cell differ-
entiated such as tyrosine hydroxylase (TH), nestin, β‐tubulin III, NSE,
and MAP‐2 caused the survival of rat fetal midbrain DA neurons in
vitro. In other study, after cell transplantation were observed
improvement the symptoms of disease in monkeys PD model, and
there were donor neuronal‐like cells which survived in the brain
tissue, detected by immunohistochemistry (Yan et al., 2013). The
HUC‐MSCs were labeled with multimodal iron oxide nanoparticles
F IGURE 2 The therapeutic potential of
mesenchymal stem cells (MSCs) in
Parkinson’s disease (PD). MSCs from
different types of organizations (human or
animal) could transplant into mouse or
monkey models of PD as preclinical
evaluation [Color figure can be viewed at
wileyonlinelibrary.com]
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conjugated with rhodamine‐B for tracing the donor cells. Then in the
rats PD model, HUC‐MSCs transplanted in the striatum area. For
visualization the labeled cells, magnetic resonance imaging technique
was used and reported about 5 × 105 cells could be efficiently
tracked in a short‐term following infusion in a neurodegenerative
disease (Sibov et al., 2014).
11 | HBM‐MSCs
HBM‐MSCs belong to mesodermal cells that are capable of differentia-
tion under proper conditions into adipocyte cells, skeletal myocyte,
osteoblast, chondrocyte, and neuronal cells. But, cell therapy with HBM‐
MSCs in rat PD model showed that the intravenous administration of
HBM‐MSCs could not prevent neurodegeneration process. While after
cell‐replacement therapy were reported improvement in the behavioral
test by intrastriatal grafting with higher cell retention in the SNpc and
corpus striatum (Jiaming & Niu, 2015). Beside in vitro survival and
differentiation rate of HBM‐MSCs is very low, therefore administration
neurotrophic factors such as glial cell line‐derived neurotrophic factor,
basic fibroblast growth factor and cAMP response element binding
protein can enhance the survival rate of transplanted BM‐MSCs, improve
cell differentiation into neuron‐like and glial‐like cells, increase striatal
dopamine concentration and finally, improve the rotational behavior of
disease in rats PD model (Yin et al., 2014).
12 | HEDSCs
HEDSCs represent a new cell source for neurological disorders,
which is abundant and can be easily isolated by a simple, safe, and
painless procedure such as Pap smears (Khademi et al., 2014; Mutlu,
Hufnagel, & Taylor, 2015). HEDSCs have positive markers for CD90,
CD105, OCT4, and CD44 and negative markers for CD31, CD34, and
CD133 (Mobarakeh et al., 2010). These stem cells capable of
differentiate DA neuron‐like cells in vitro, which exhibit dendritic‐
like and axon‐like projections and express neural cell markers
including TH and nestin (Noureddini et al., 2012; Wolff et al.,
2011). After cell transplantation into the striatum in monkeys PD
model, the cells could engraft into the striatum area, migrate to the
SNpc, and spontaneously differentiated in vivo. The result showed
increasing TH positive cells on the transplanted region and increasing
dopamine metabolite concentrations were also observed (Wolff et al.,
2015). HEDSCs are the best of the mesenchymal stem‐like cell for
generate DA neural cells by cell‐replacement therapy. Cell expres-
sion with a positive marker of CD90, platelet‐derived growth factor
and CD146 can differentiate into DA neurons that exhibit axon
projections, pyramidal cell bodies and dendritic projection that
recapitulate synapse formation; these stem cells also express the
neural marker nestin and TH, the rate‐limiting enzyme in dopamine
synthesis. Scientists could transplant HEDSCs successfully into
MPTP PD mice model (Wolff et al., 2011). Also, endometrial stem
cells were collected from monkey’s uterus and transplanted into an
MPTP exposed monkey model of PD (Wolff et al., 2015). In the
transplanted region, endometrial stem cells can survive and also
according to the pathotropism effect these cells are capable to
migrate to the lesion area and spontaneously differentiate to the
target cells. Pathotropism is an ability of stem cells to specifically
migrate to pathological sites, such as an inflamed area. HEDSCs open
a therapeutic way by rescuing dopamine concentration in PD animal
model and these stem cells are an important source of stem cells that
can isolate from a routine office procedure. Endometrial stem cells
have the ability for use as an autologous or allogenic stem cell source,
so resolve concerns regarding rejection in human beings. The lack of
rejection feature for HEDSCs in animal model is due to the immune
provided by the blood–brain barrier and this property leads to the
excellence of them compared with other type of stem cells (Chopp &
Li, 2002; Li et al., 2001; Wolff et al., 2011). An important advantage
of HEDSCs is very low tumorigenicity potential in the transplanted
area. Cell‐replacement therapy with HEDSCs introduces a promising
future for curing PD due to the lack of gliosis. Based on the
therapeutic potential we mentioned here, HEDSCs can become a
F IGURE 3 Mesenchymal stem cells (MSCs) transplantation.
MSCs from human endometrium are dissected, and the tissues are
prepared as dissociated cell suspensions. The resulting product is
injected through a needle into the striatum [Color figure can be
viewed at wileyonlinelibrary.com]
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valuable source of allogenic stem cells to be used for regenerative
medicine (Sharif et al., 2017; Figure 3).
13 | CONCLUSIONS
Stem cells have become attractive candidates for cell therapy in
neurological disorders including PD. Stem cell therapy especially with
HEDSCs shows a promising technology for PD treatment in which
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